Theralase Technologies Inc. Market Cap ($40.43 Million)
Market Cap & Net Worth: Theralase Technologies Inc. (TLT)
Theralase Technologies Inc. market cap. Theralase Technologies Inc. (V:TLT) has a market capitalization of $40.43 Million (CA$55.89 Million) as of November 4, 2026. Listed on the V stock exchange, this Canada-based company holds position #22479 globally and #791 in its home market, demonstrating a -10.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theralase Technologies Inc.'s stock price CA$0.18 by its total outstanding shares 310483818 (310.48 Million). Also see how efficiently does Theralase Technologies Inc. generate cash for how efficiently the company converts equity into cash flow.
Theralase Technologies Inc. Market Cap History (2015–2026)
Theralase Technologies Inc. market cap history from 2015 to 2026. Data shows change from $96.58 Million to $40.43 Million (-3.92% CAGR). Check Theralase Technologies Inc. (TLT) stock price for real-time trading data and today's change.
Theralase Technologies Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theralase Technologies Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Theralase Technologies Inc. to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
46.76x
Theralase Technologies Inc.'s market cap is 46.76 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $57.27 Million | $1.92 Million | -$4.92 Million | 29.85x | N/A |
| 2017 | $55.03 Million | $2.34 Million | -$6.09 Million | 23.49x | N/A |
| 2018 | $70.75 Million | $1.73 Million | -$3.36 Million | 40.80x | N/A |
| 2019 | $76.36 Million | $964.05K | -$7.43 Million | 79.21x | N/A |
| 2020 | $42.67 Million | $929.12K | -$5.61 Million | 45.93x | N/A |
| 2021 | $84.22 Million | $780.64K | -$4.42 Million | 107.89x | N/A |
| 2022 | $71.87 Million | $1.14 Million | -$5.25 Million | 63.12x | N/A |
| 2023 | $40.43 Million | $1.07 Million | -$4.57 Million | 37.77x | N/A |
| 2024 | $59.52 Million | $1.03 Million | -$4.26 Million | 57.59x | N/A |
| 2025 | $38.18 Million | $816.47K | -$4.12 Million | 46.76x | N/A |
Competitor Companies of TLT by Market Capitalization
Companies near Theralase Technologies Inc. in the global market cap rankings as of November 4, 2026. Also see Theralase Technologies Inc. balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Theralase Technologies Inc. by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $190.23 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $119.12 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #226 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $190.23 Billion | $109.40 |
| #204 | Stryker Corporation | NYSE:SYK | $119.12 Billion | $310.55 |
| #226 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $98.88 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Theralase Technologies Inc. (2015–2026)
Market capitalization of Theralase Technologies Inc. from 2015 to today. Between 2015 and today, Theralase Technologies Inc.'s market cap moved from $96.58 Million to $ 40.43 Million, with a yearly change of -3.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$40.43 Million | +5.88% |
| 2025 | CA$38.18 Million | -35.85% |
| 2024 | CA$59.52 Million | +47.22% |
| 2023 | CA$40.43 Million | -43.75% |
| 2022 | CA$71.87 Million | -14.67% |
| 2021 | CA$84.22 Million | +97.37% |
| 2020 | CA$42.67 Million | -44.12% |
| 2019 | CA$76.36 Million | +7.94% |
| 2018 | CA$70.75 Million | +28.57% |
| 2017 | CA$55.03 Million | -3.92% |
| 2016 | CA$57.27 Million | -40.70% |
| 2015 | CA$96.58 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Theralase Technologies Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.43 Million USD |
| MoneyControl | $40.43 Million USD |
| MarketWatch | $40.43 Million USD |
| marketcap.company | $40.43 Million USD |
| Reuters | $40.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form … Read more